RecruitingNot Applicable

Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy

United States400 participantsStarted 2023-03-01

Plain-language summary

This single-center, 400-patient, randomized controlled trial assesses the impact of a patient- and provider-facing EPIC Best Practice Advisory (BPA; alert-based computerized decision support tool) to increase guideline-directed utilization of statin and statin-alternative oral LDL-C lowering therapies in patients with PAD who are not being prescribed LDL-C-lowering therapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All patients ≥ 18 years old * Seen in Cardiovascular Medicine Clinic, Primary Care, Podiatry, Vascular Surgery, and Diabetology * Medical history entry, visit diagnosis, or problem list entry of PAD * Not prescribed LDL-C-lowering therapy Exclusion Criteria: * Patients taking a statin, ezetimibe, bempedoic acid, a PCSK9 inhibitor, inclisiran or a combination will be excluded

What they're measuring

Frequency of prescription of oral LDL-C-lowering therapy

Timeframe: 90 days

Trial details

NCT IDNCT06300450

SponsorBrigham and Women's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-02-28

Contact for this trial

Gregory Piazza

6177326984 gpiazza@bwh.harvard.edu

View on ClinicalTrials.gov More Peripheral Artery Disease trials